Norepinephrine in Neurodegeneration: A Coerulean Target

Alzheimer’s (AD) and Parkinson’s (PD) diseases are the two most common neurodegenerative disorders in older adults. Currently over 6 million Americans have been diagnosed with AD or PD, and this incidence is expected to increase dramatically in the near future [1,2]. Many recent advances in medicine have increased lifespan, and consequently an aging population has contributed to the burgeoning load of persons suffering from AD and PD. Both disorders are in the top 15 leading causes of death in the United States [3], and have no effective cures nor treatments that alter their progression. Since clinical diagnosis often occurs many years after the onset of neurodegeneration, early detection of neuropathological features and potentially overlooked prodromal symptoms may benefit future treatment strategies.

[1]  D. Salmon,et al.  The neuropsychological profile of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[2]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[3]  Angie A. Kehagia,et al.  Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease , 2010, The Lancet Neurology.

[4]  P. Robert,et al.  Dysexecutive syndrome: Diagnostic criteria and validation study , 2010, Annals of neurology.

[5]  T R Ten Have,et al.  Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease , 2010, Neurology.

[6]  F. Kirchhoff,et al.  Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine , 2010, Proceedings of the National Academy of Sciences.

[7]  H. Braak,et al.  A timeline for Parkinson's disease. , 2010, Parkinsonism & related disorders.

[8]  C. Waters,et al.  Current strategies in the treatment of Parkinson’s disease and a personalized approach to management , 2009, Expert review of neurotherapeutics.

[9]  J. Kulisevsky,et al.  Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances , 2009, Journal of neural transmission.

[10]  Melissa Gerstenhaber,et al.  Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study , 2009, Movement disorders : official journal of the Movement Disorder Society.

[11]  C. Hawkes.  The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it? , 2008, Movement disorders : official journal of the Movement Disorder Society.

[12]  J. McGaughy,et al.  Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex , 2008, Psychopharmacology.

[13]  D. Weinshenker,et al.  Functional consequences of locus coeruleus degeneration in Alzheimer's disease. , 2008, Current Alzheimer research.

[14]  M. Corbetta,et al.  The Reorienting System of the Human Brain: From Environment to Theory of Mind , 2008, Neuron.

[15]  H. Eichenbaum,et al.  Noradrenergic, but not cholinergic, deafferentation of prefrontal cortex impairs attentional set-shifting , 2008, Neuroscience.

[16]  G. Aston-Jones,et al.  Light deprivation damages monoamine neurons and produces a depressive behavioral phenotype in rats , 2008, Proceedings of the National Academy of Sciences.

[17]  F. Fornai,et al.  Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. , 2007, Current medicinal chemistry.

[18]  K. Rommelfanger,et al.  Norepinephrine: The redheaded stepchild of Parkinson's disease. , 2007, Biochemical pharmacology.

[19]  T. Robbins,et al.  Lesions of the dorsal noradrenergic bundle impair attentional set‐shifting in the rat , 2007, The European journal of neuroscience.

[20]  P. Calabresi,et al.  A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine–acetylcholine synaptic balance , 2006, The Lancet Neurology.

[21]  Yasuo Terayama,et al.  Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease , 2006, Neuroreport.

[22]  C. Berridge,et al.  Organization of noradrenergic efferents to arousal‐related basal forebrain structures , 2006, The Journal of comparative neurology.

[23]  Angela J. Yu,et al.  Phasic norepinephrine: A neural interrupt signal for unexpected events , 2006, Network.

[24]  S. Sara,et al.  Network reset: a simplified overarching theory of locus coeruleus noradrenaline function , 2005, Trends in Neurosciences.

[25]  Jonathan D. Cohen,et al.  An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. , 2005, Annual review of neuroscience.

[26]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[27]  S. Sara,et al.  Reward expectation, orientation of attention and locus coeruleus‐medial frontal cortex interplay during learning , 2004, The European journal of neuroscience.

[28]  W. Schmidt,et al.  Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6‐hydroxydopamine‐induced partial degeneration of substantia nigra in rats , 2003, The European journal of neuroscience.

[29]  C. Berridge,et al.  The locus coeruleus–noradrenergic system: modulation of behavioral state and state-dependent cognitive processes , 2003, Brain Research Reviews.

[30]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[31]  Chris Zarow,et al.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. , 2003, Archives of neurology.

[32]  L. Beckett,et al.  Annual Incidence of Alzheimer Disease in the United States Projected to the Years 2000 Through 2050 , 2001, Alzheimer disease and associated disorders.

[33]  M. Ruberg,et al.  Noradrenaline provides long‐term protection to dopaminergic neurons by reducing oxidative stress , 2001, Journal of neurochemistry.

[34]  F. Fornai,et al.  The role of the locus coeruleus in the development of Parkinson's disease , 2000, Neuroscience & Biobehavioral Reviews.

[35]  H. Braak,et al.  Parkinson’s disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system , 2000, Acta Neuropathologica.

[36]  B Renault,et al.  Automatic attentional shifts induced by a noradrenergic drug in Alzheimer's disease: evidence from evoked potentials. , 1999, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[37]  E. Abercrombie,et al.  Relationship between locus coeruleus discharge rates and rates of norepinephrine release within neocortex as assessed by in vivo microdialysis , 1999, Neuroscience.

[38]  J. Cohen,et al.  The role of locus coeruleus in the regulation of cognitive performance. , 1999, Science.

[39]  G. Aston-Jones,et al.  Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus , 1996, Brain Research.

[40]  J. Hedreen,et al.  The locus ceruleus and dementia in Parkinson's disease , 1993, Neurology.

[41]  Wade K. Smith,et al.  Disease‐specific patterns of locus coeruleus cell loss , 1992, Annals of neurology.

[42]  V. Chan‐Palay.  Depression and dementia in Parkinson's disease. Catecholamine changes in the locus ceruleus, a basis for therapy. , 1991, Advances in neurology.

[43]  A. C. Roberts,et al.  Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: Evidence for a specific attentional dysfunction , 1989, Neuropsychologia.

[44]  V. Chan‐Palay,et al.  Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression , 1989, The Journal of comparative neurology.

[45]  B. Scatton,et al.  Parkinson's disease and dementia , 1987, Neurology.

[46]  W. T. Nickell,et al.  The brain nucleus locus coeruleus: restricted afferent control of a broad efferent network. , 1986, Science.

[47]  M. Yahr,et al.  Dementia in idiopathic Parkinson's disease , 1986, Journal of Neural Transmission.

[48]  Y. Agid,et al.  Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease , 1983, Brain Research.

[49]  F. Bloom,et al.  Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. , 1983, Physiological reviews.

[50]  F. Bloom,et al.  Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle , 1981, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[51]  B. Winblad,et al.  Changes in the Brain Catecholamines in Patients with Dementia of Alzheimer Type , 1979, British Journal of Psychiatry.

[52]  G. Aston-Jones,et al.  A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. , 2011, Journal of Alzheimer's disease : JAD.

[53]  Mathias Hoehn,et al.  Locus Ceruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice , 2006, The Journal of Neuroscience.

[54]  B. Jones.  Activity, modulation and role of basal forebrain cholinergic neurons innervating the cerebral cortex. , 2004, Progress in brain research.

[55]  G. Aston-Jones,et al.  Role of the locus coeruleus in emotional activation. , 1996, Progress in brain research.

[56]  V. Chan‐Palay,et al.  Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease. , 1991, Progress in brain research.